Mixed Phase III results for Dainippon Sumitomo's antipsychotic lurasidone
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma's once-daily atypical antipsychotic lurasidone has shown mixed results in patients with schizophrenia, where one out of the three doses investigated in its first Phase III clinical trial met the primary endpoint. The results were presented at the annual meeting of the American Psychiatric Association in San Francisco.